Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
暂无分享，去创建一个
E. Winer | A. DeMichele | H. Burstein | M. Regan | C. Anders | M. Cristofanilli | S. Wander | C. H. Bartlett | E. Mayer | A. Forero-Torres | M. Rimawi | Cynthia X. Ma